First pharma worth a trillion dollars

Eli Lilly has become the first trillion-dollar pharma. The drugmaker hit a US$1 trillion valuation on the US stockmarket on Friday, having added more than US$400 billion to its market cap since early August.

In 2017, when Dave Ricks took over as CEO, the company was worth US$81 billion.

Lilly’s shares were trading at about US$1059 each at the close on Friday, up 36 per cent so far this year, 619 per cent over five years, and 1167 per cent over 10 years.

To see the whole article please log in.

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here